FDA

Medicare Won’t Pay for Controversial Alzheimer’s Drug Aduhelm Without A New Trial

In a key decision, the Centers for Medicare and Medicaid Services (CMS) said today that Medicare will not pay for the controversial Alzheimer’s drug Adulhelm until it sees positive results from a government-approved trial. In bureaucratic language: “Monoclonal antibodies directed against amyloid for the treatment of [Alzheimer’s Disease] provided outside of the CMS approved randomized controlled trials and trials supported [...]

By |2022-01-11T17:46:04-05:00January 11th, 2022|dementia|0 Comments

What’s Behind Biogen’s Move To Cut Prices On Its Controversial Alzheimer’s Drug Aduhelm?

This week, drugmaker Biogen made a stunning announcement: It is going to cut in half the price of its controversial Alzheimer’s drug Aduhelm. Instead of selling the infusion drug for $56,000 annually to a typical user it will charge $28,000-a-year. It is, to say the least, unusual, for the maker of a potential blockbuster drug to cuts its price just [...]

By |2021-12-23T14:28:34-05:00December 23rd, 2021|dementia|0 Comments

With Medicare Undecided On Whether To Pay, Alzheimer’s Drug Maker Biogen Offers Free Doses

A funny thing happened on the way to that $56,00-a-year Alzheimer’s drug: Payers are reluctant to pay, providers are reluctant to prescribe, and the price is coming down—at least for some patients. It is a tale  that could push Congress to allow Medicare to negotiate drug prices. Reuters reports that Biogen, which sells the controversial medication it calls Aduhelm, is [...]

By |2021-09-01T15:11:40-04:00September 1st, 2021|dementia|0 Comments

Will Medicare Pay For The New Alzheimer’s Drug?

Last month, The Food and Drug Administration (FDA) approved a controversial new drug to treat people with Alzheimer’s disease. But even though the FDA allowed the drug to be sold, Medicare is not required to pay for it. And yesterday, the Centers for Medicare & Medicaid Services (CMS) began a process to determine whether Medicare will establish a national coverage [...]

By |2021-07-13T13:57:06-04:00July 13th, 2021|dementia|0 Comments

FDA’s Approval Of A New Alzheimer’s Drug Shows What’s Wrong With The Way We Care For Frail Older Adults

FDA’s decision last week to approve a new “Alzheimer’s disease treatment,” and the buzz that surrounds it, is a symptom of all that is wrong with the way we care for frail older adults in the US. Rather than providing the supports that people with chronic conditions desperately need, and that evidence shows works, we prefer to chase butterflies. In [...]

By |2021-06-15T11:54:04-04:00June 15th, 2021|long-term care, Uncategorized|0 Comments

What Does FDA’s Approval Of A New Alzheimer’s Drug Mean?

In a highly controversial decision, the FDA gave accelerated approval to the first drug that could slow the progression of Alzheimer’s disease. But the approval does not say the FDA thinks the drug actually will treat the disease. Rather, FDA carefully states that the drug, with the chemical name aducanumab and the brand name Aduhelm, reduces a substance on the [...]

By |2021-06-07T17:50:37-04:00June 7th, 2021|dementia|5 Comments